BDBM256563 US10435361, Example 62::US9481648, 62::US9790174, Example 62

SMILES COCCOCCOCCNC(=O)c1cc(Nc2cc(Oc3ccc(NC(=O)Nc4cc(cc(c4)C(C)(C)C)C(N)=O)c4ccccc34)ccn2)cc(c1)C#C

InChI Key InChIKey=WYWRLMHPIIOOOI-UHFFFAOYSA-N

Data  8 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 8 hits for monomerid = 256563   

TargetMitogen-activated protein kinase 14(Human)
Respivert

US Patent
LigandPNGBDBM256563(US9481648, 62 | US9790174, Example 62 | US10435361...)
Affinity DataIC50: 32nMAssay Description:Method 2: This method follows the same steps as Method 1 above, but utilises a higher concentration of the p38 MAPKα protein (2.5 uL of 200 ng/...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetMitogen-activated protein kinase 14(Human)
Respivert

US Patent
LigandPNGBDBM256563(US9481648, 62 | US9790174, Example 62 | US10435361...)
Affinity DataIC50: 32nMAssay Description:The following two assay variants can be used for determination of p38 MAPKα inhibition.Method 1The inhibitory activities of test compounds again...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256563(US9481648, 62 | US9790174, Example 62 | US10435361...)
Affinity DataIC50: 44nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetProto-oncogene tyrosine-protein kinase Src(Human)
Respivert

US Patent
LigandPNGBDBM256563(US9481648, 62 | US9790174, Example 62 | US10435361...)
Affinity DataIC50: 44nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetTyrosine-protein kinase SYK(Human)
Respivert

US Patent
LigandPNGBDBM256563(US9481648, 62 | US9790174, Example 62 | US10435361...)
Affinity DataIC50: 1.32E+3nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetTyrosine-protein kinase SYK(Human)
Respivert

US Patent
LigandPNGBDBM256563(US9481648, 62 | US9790174, Example 62 | US10435361...)
Affinity DataIC50: 1.32E+3nMAssay Description:The inhibitory activities of compounds of the invention against c-Src and Syk enzymes (Invitrogen), are evaluated in a similar fashion to that descri...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM256563(US9481648, 62 | US9790174, Example 62 | US10435361...)
Affinity DataIC50: 1.06E+4nMAssay Description:Method 2: This method follows the same steps as Method 1 above, but utilises a shorter period of mixing of the test compound (105 minutes instead of ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/30/2017
Entry Details
US Patent

TargetGlycogen synthase kinase-3 alpha(Human)
Respivert

US Patent
LigandPNGBDBM256563(US9481648, 62 | US9790174, Example 62 | US10435361...)
Affinity DataIC50: 1.06E+4nMAssay Description:The inhibitory activities of compounds of the invention against the GSK 3α enzyme isoform (Invitrogen), are evaluated by determining the level o...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/9/2019
Entry Details
US Patent